Medicine & pharma · Official intelligence
EMA approves Ruxolitinib Krka for myelofibrosis and polycythaemia vera
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion on November 12, 2026, recommending marketing authorization for Ruxolitinib Krka. This generic medicine by KRKA is indicated for treating myelofibrosis and polycythaemia vera, expanding treatment options in the EU.
Original source
Read the source — ema.europa.eu ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.